CAMKK2 and early-onset autosomal dominant Alzheimer disease: Recent progress in developing highly selective and potent CaMKK2 inhibitors and ligand-directed degraders [85–90] has advanced the field a step closer to realizing the therapeutic potential of targeting CaMKK2 for treating prostate cancer and other diseases associated with aberrant CaMKK2 activation, including Alzheimer’s disease and liver steatosis.